FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394412> ?p ?o ?g. }

• W4308394412 abstract "<h3>Background</h3> Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1(PD-1) blockade therapy has been approved for the treatment of many malignancies whereas the majority of patients with solid tumors do not respond well.¹ B7-H3, another newly identified immune checkpoint molecule, has limited expression in normal human tissues while highly expressed on cancer cells and tumor-infiltrating antigen-presenting cells (APCs), which is associated with T-cell exhaustion in cancer patients. In addition, B7-H3 is overexpressed by the tumor-associated vasculature and stromal fibroblasts, and contributes to the development of cancer through both immune-dependent and nonimmune routes.² However, clinical therapeutic antibodies targeting B7-H3, such as Enobituzumab, have not shown an immune checkpoint blockade effect. ATG-027, a novel B7-H3/PD-L1 bispecific antibody, was designed to exert the anti-tumor efficiency through reinforcing T cell activation by dual-blocking of B7-H3 and PD-L1, antibody-dependent cellular cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). <h3>Methods</h3> ATG-027 was developed by introducing high-affinity PD-L1 scFv into a human IgG1 B7-H3 monoclonal antibody (mAb). The bispecific antibody employed wild type Fc domain which enables ADCC and ADCP effects. A series of in vitro studies were performed to evaluate the immune regulating function and anti-tumor efficacy of ATG-027. The in vivo efficacy of ATG-027 was evaluated in mice bearing syngeneic MC38 colorectal cancer cells overexpressing human B7-H3 (MC38-hB7-H3). <h3>Results</h3> In the cell-based assay, ATG-027 binds with nanomolar affinity to both B7-H3 and PD-L1 expressing cells. ATG-027 demonstrated higher ADCC/CDC activity compared with anti-PD-L1 and anti-B7-H3 parental antibodies. ATG-027 also demonstrated greater ADCP potency than anti-PD-L1, anti-B7-H3, or the combination. Interestingly, in a Mixed Lymphocyte Reaction (MLR) experiment to assess the T cell activation, the B7-H3 parental antibody (30-C7) or the Fab region of 30-C7 (30-C7-Fab) induced robust IL-2 and IFNγ production, indicating T cell activating function, whereas Enobituzumab showed no effect in the experiment (figure 1). ATG-027 also demonstrated superior in vivo anti-tumor activity in mouse MC38-hB7-H3 models compared to parental antibodies. Biweekly dosing of 7.5mg/kg ATG-027 induced tumor shrinkage or complete tumor regression. <h3>Conclusions</h3> By binding to a specific epitope of B7-H3, ATG-027 blocks the protein’s inhibitory function, leading to strong T cell activation. ATG-027 can also inhibit the interaction between PD1/PD-L1 to rescue T cell activity suppression. ATG-027’s dual T cell activation function and powerful ADCC, CDC, and ADCP properties contribute to its promising anti-tumor efficacy in preclinical models. <h3>References</h3> Cai D, J Li, D Liu, S Hong, Q Qiao, Q Sun, P Li, N Lyu, T Sun, S Xie, L Guo, L Ni, L Jin, and C Dong. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. <i>Cellular & Molecular Immunology</i> 2020;<b>17</b>: 227–236. Zhou WT, and WL Jin. B7-H3/CD276: An Emerging Cancer Immunotherapy. <i>Frontiers in Immunology</i> 2021;<b>12</b>: 701006. <h3>Ethics Approval</h3> The protocol and any amendment(s) or procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio to execution with an AUP number or IACUC approval number for each animal study.All studies were conducted following an approved IACUC protocol. AUP NO. 2104-09-2186." @default.
• W4308394412 created "2022-11-11" @default.
• W4308394412 creator A5001996286 @default.
• W4308394412 creator A5005453663 @default.
• W4308394412 creator A5015186924 @default.
• W4308394412 creator A5030401301 @default.
• W4308394412 creator A5033143394 @default.
• W4308394412 creator A5063287594 @default.
• W4308394412 creator A5074445429 @default.
• W4308394412 date "2022-11-01" @default.
• W4308394412 modified "2023-10-18" @default.
• W4308394412 title "1397 ATG 027 a first in class B7 H3 PD L1 bispecific antibody shows potent T cell activation capability and in vivo anti tumor efficacy" @default.
• W4308394412 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1397" @default.
• W4308394412 hasPublicationYear "2022" @default.
• W4308394412 type Work @default.
• W4308394412 citedByCount "0" @default.
• W4308394412 crossrefType "proceedings-article" @default.
• W4308394412 hasAuthorship W4308394412A5001996286 @default.
• W4308394412 hasAuthorship W4308394412A5005453663 @default.
• W4308394412 hasAuthorship W4308394412A5015186924 @default.
• W4308394412 hasAuthorship W4308394412A5030401301 @default.
• W4308394412 hasAuthorship W4308394412A5033143394 @default.
• W4308394412 hasAuthorship W4308394412A5063287594 @default.
• W4308394412 hasAuthorship W4308394412A5074445429 @default.
• W4308394412 hasBestOaLocation W43083944121 @default.
• W4308394412 hasConcept C109316439 @default.
• W4308394412 hasConcept C121608353 @default.
• W4308394412 hasConcept C126322002 @default.
• W4308394412 hasConcept C147483822 @default.
• W4308394412 hasConcept C150903083 @default.
• W4308394412 hasConcept C159654299 @default.
• W4308394412 hasConcept C16930146 @default.
• W4308394412 hasConcept C202751555 @default.
• W4308394412 hasConcept C203014093 @default.
• W4308394412 hasConcept C207001950 @default.
• W4308394412 hasConcept C2776090121 @default.
• W4308394412 hasConcept C2777701055 @default.
• W4308394412 hasConcept C2780851360 @default.
• W4308394412 hasConcept C40677261 @default.
• W4308394412 hasConcept C45121317 @default.
• W4308394412 hasConcept C502942594 @default.
• W4308394412 hasConcept C542903549 @default.
• W4308394412 hasConcept C55493867 @default.
• W4308394412 hasConcept C71924100 @default.
• W4308394412 hasConcept C86803240 @default.
• W4308394412 hasConcept C8891405 @default.
• W4308394412 hasConcept C96232424 @default.
• W4308394412 hasConceptScore W4308394412C109316439 @default.
• W4308394412 hasConceptScore W4308394412C121608353 @default.
• W4308394412 hasConceptScore W4308394412C126322002 @default.
• W4308394412 hasConceptScore W4308394412C147483822 @default.
• W4308394412 hasConceptScore W4308394412C150903083 @default.
• W4308394412 hasConceptScore W4308394412C159654299 @default.
• W4308394412 hasConceptScore W4308394412C16930146 @default.
• W4308394412 hasConceptScore W4308394412C202751555 @default.
• W4308394412 hasConceptScore W4308394412C203014093 @default.
• W4308394412 hasConceptScore W4308394412C207001950 @default.
• W4308394412 hasConceptScore W4308394412C2776090121 @default.
• W4308394412 hasConceptScore W4308394412C2777701055 @default.
• W4308394412 hasConceptScore W4308394412C2780851360 @default.
• W4308394412 hasConceptScore W4308394412C40677261 @default.
• W4308394412 hasConceptScore W4308394412C45121317 @default.
• W4308394412 hasConceptScore W4308394412C502942594 @default.
• W4308394412 hasConceptScore W4308394412C542903549 @default.
• W4308394412 hasConceptScore W4308394412C55493867 @default.
• W4308394412 hasConceptScore W4308394412C71924100 @default.
• W4308394412 hasConceptScore W4308394412C86803240 @default.
• W4308394412 hasConceptScore W4308394412C8891405 @default.
• W4308394412 hasConceptScore W4308394412C96232424 @default.
• W4308394412 hasLocation W43083944121 @default.
• W4308394412 hasOpenAccess W4308394412 @default.
• W4308394412 hasPrimaryLocation W43083944121 @default.
• W4308394412 hasRelatedWork W2067077431 @default.
• W4308394412 hasRelatedWork W2116591654 @default.
• W4308394412 hasRelatedWork W2122854061 @default.
• W4308394412 hasRelatedWork W2443772760 @default.
• W4308394412 hasRelatedWork W2476973230 @default.
• W4308394412 hasRelatedWork W2984962695 @default.
• W4308394412 hasRelatedWork W4225811843 @default.
• W4308394412 hasRelatedWork W4283731173 @default.
• W4308394412 hasRelatedWork W4291367166 @default.
• W4308394412 hasRelatedWork W4360983034 @default.
• W4308394412 isParatext "false" @default.
• W4308394412 isRetracted "false" @default.
• W4308394412 workType "article" @default.